PRIMARY STUDY
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review
Key Findings: This review finds that several minor cannabinoids, cannabidivarin (CBDV), cannabidiforol (CBDP), cannabichromene (CBC), tetrahydrocannabivarin (THCV), cannabigerolic acid (CBGA), cannabigerol (CBG), cannabielsoin (CBE), cannabimovone (CBM), and cannabinol (CBN), have the potential to provide therapeutic options in alleviating dermatological conditions.
Type of Study: Meta-analysis
Study Result: Positive
Research Location(s): Poland
Year of Pub: 2023
Cannabinoids Studied: Cannabichromene (CBC), Cannabigerol (CBG), Cannabinol (CBN), Cannabigerolic Acid (CBG-a), WIN-x Synthetic Cannabinoids, Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), Endocannabinoid (unspecified), Tetrahydrocannabivarin (THCV), Cannabidivarin (CBDV)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, TRPA1, TRPV1, PPAR - Gamma, PPARs
Ligands Studied: Anti-inflammatory cytokines, Pro-inflammatory cytokines
Citation: Kwiecień E, Kowalczuk D. Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases-A Synthetic Review. Molecules. 2023 Aug 20;28(16):6149. doi: 10.3390/molecules28166149. PMID: 37630401; PMCID: PMC10459035.
